Article

USPSTF Recommendation Emphasizes Patient Choice for Prostate Cancer Screening

Author(s):

The recommendation means more men could be screened, now that the recommendation has been upgraded from its existing D recommendation to a grade C recommendation.

In its final recommendation,

the US Preventive Services Task Force (USPSTF) recommends that men aged 55 to 69 make their own decision on whether to be screened periodically for prostate cancer after they have had a conversation with their physician on potential benefits and harms.

The recommendation means more men could be screened, now that the recommendation has been upgraded from its existing D recommendation to a grade C recommendation. In 2012, the task force recommended against prostate-specific antigen (PSA)-based screening for prostate cancer.

For men aged 70 and older, the potential benefits do not outweigh the harms, and they should not be routinely screened, according to the final recommendation, which is in accordance with the 2012 statement.

USPSTF’s statement emphasized the importance of shared-decision making between patients and physicians. “That several guidelines now recommend a shared decision making approach for prostate cancer screening is a strong indication that, for this decision, the available data do not allow the physician to recommend a course of action without further understanding what is important to the patients—which can only happen by spending time in discussion,” according to the statement.

Click to continue reading on The American Journal of Managed Care.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards